Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;46(3):444-450.
doi: 10.1111/ced.14481. Epub 2020 Nov 12.

Skin manifestations of COVID-19 in children: Part 1

Affiliations
Review

Skin manifestations of COVID-19 in children: Part 1

D Andina et al. Clin Exp Dermatol. 2021 Apr.

Abstract

The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestation of COVID-19, chilblain-like lesions. In Part 2, we review other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome, while in Part 3, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children, for both COVID-19 and any other pre-existing conditions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a–d) The spectrum of acral ischaemic lesions in children in the setting of COVID‐19.

References

    1. Recalcati S. Cutaneous manifestations in COVID‐19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34: e212–13. - PubMed
    1. Mazzotta F, Troccoli T. Acute acro‐ischemia in the child at the time of COVID‐19. Eur J Pediat Dermatol 2020; 30: 71–4.
    1. Cappel JA, Wetter DA. Clinical characteristics, etiologic associations, laboratory findings, treatment, and proposal of diagnostic criteria of pernio (chilblains) in a series of 104 patients at Mayo Clinic, 2000 to 2011. Mayo Clin Proc 2014; 89: 207–15. - PubMed
    1. Ozmen M, Kurtoglu V, Can G et al. The capillaroscopic findings in idiopathic pernio: is it a microvascular disease? Mod Rheumatol 2013; 23: 897–903. - PubMed
    1. Hughes M, Rogers S, Lepri G et al. Further evidence that chilblains are a cutaneous manifestation of COVID‐19 infection. Br J Dermatol 2020; 183: 596–8. 10.1111/bjd.19243. - DOI - PMC - PubMed

Substances